Ivermectin for Rosacea — How Does It Compare to Azelaic Acid?
Rosacea is a completely different disease from common acne, despite the confusingly similar name — and it needs different treatment. Ivermectin 1% cream is one of the newer treatment options, tested in two 40-week extension trials against azelaic acid 15%. We explain exactly what these trials showed, what they didn't show, and why this is primarily long-term safety data rather than a classic head-to-head efficacy contest.
The name is misleading, and that's the main source of confusion: rosacea is not a variant or prolonged form of common acne, but a separate, chronic inflammatory skin disease of the face. It primarily involves blood vessels and the skin's innate immune mechanisms, not sebaceous glands clogged by excess sebum and dead skin cells, as in classic teenage acne. In practice, this means that treatments effective for common acne — strong exfoliating agents, some oral antibiotics used differently than in rosacea, aggressive peels — can be ineffective in rosacea, and sometimes even worsen symptoms.
The clinical picture is also different. Rosacea typically affects the central part of the face — cheeks, nose, forehead, chin — and causes persistent redness, visible dilated blood vessels (telangiectasia), and in the papulopustular form, also red papules and pustules resembling acne, but without the typical comedones. In some patients, tissue overgrowth develops, mainly around the nose (rhinophyma), and the disease can also be associated with eye irritation (ocular rosacea). This article focuses on the papulopustular form, since that's exactly what the trial discussed below evaluated for ivermectin.
Where the idea of ivermectin for rosacea came from
Ivermectin is known primarily as an antiparasitic drug, used for decades to treat scabies and certain parasitic infestations, among other things. Its presence in rosacea dermatology stems from a hypothesis studied for years: some rosacea patients have elevated numbers of Demodex folliculorum mites, tiny parasites that naturally live in the hair follicles of facial skin, which in excess may worsen local inflammation. Ivermectin has both antiparasitic activity against Demodex and a direct anti-inflammatory effect independent of the mites themselves.
This is still a studied hypothesis, not an established fact
The link between Demodex mite counts and rosacea severity is the subject of active research, not a fully confirmed causal mechanism. Ivermectin may work both by reducing Demodex and through independent anti-inflammatory action — the clinical trial discussed in this article evaluated the end result (safety and skin condition), not which of these mechanisms is responsible for it.
Ivermectin 1% cream received approval for treating inflammatory lesions of papulopustular rosacea after two earlier phase III trials showed its superiority over placebo (vehicle without active substance) in reducing skin lesions and overall clinical assessment. It was the participants of those two phase III trials who were later invited to a longer follow-up, described in the next section of this article.
What the trial comparing ivermectin with azelaic acid showed
Azelaic acid at a 15% concentration is one of the established, long-used topical therapies for papulopustular rosacea, with a well-documented safety profile. A natural clinical question, then, was how the newer ivermectin cream compares to it over longer, multi-month use — not just versus placebo.
Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials
Moderate evidence
Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z et al. (Ivermectin Phase 3 Study Group) · Journal of Drugs in Dermatology · 2014
Two 40-week extension trials, continuing earlier phase III trials of ivermectin 1% cream in papulopustular rosacea. Participants originally treated with ivermectin 1% continued that therapy, while participants originally receiving placebo (vehicle) were switched to azelaic acid 15% gel — total treatment time reached up to 52 weeks. Ivermectin 1% cream proved safe throughout the follow-up period, with a lower rate of treatment-related adverse events compared to the azelaic acid group. No participant in the ivermectin group discontinued the study due to a treatment-related adverse event. Ivermectin's efficacy was maintained during the extended follow-up — the proportion of patients with an IGA (Investigator Global Assessment) rating of "clear" or "almost clear" skin was higher at the end of the study than at the start. The publication does not report the exact group sizes or percentage values or p-values for the adverse event comparison — the abstract is limited to descriptive conclusions.
This is a safety study, not a classic efficacy showdown
Moderate evidence
It's worth being precise about what this research project actually evaluated. It was a long-term safety and tolerability project (safety extension study), not a randomized head-to-head trial in which both groups were randomly assigned to ivermectin or azelaic acid from the start. In practice: the ivermectin group consisted of people continuing a therapy they had already tolerated well, while the azelaic acid group consisted of people who had received placebo in the original trial and only switched to active treatment in the extension phase. This setup naturally favors a better safety profile in the group continuing an already-known therapy and makes it harder to cleanly interpret the difference in adverse events between the two substances.
A true head-to-head trial: ivermectin vs metronidazole
The safety-extension data against azelaic acid, discussed above, has a built-in limitation: the two groups didn't start from the same randomized point. A separate, differently designed trial fills that gap by comparing ivermectin directly against metronidazole — another established first-line topical treatment for rosacea — with both arms randomized to active treatment from day one.
Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial
Strong evidence
Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J, Ivermectin Phase III study group · British Journal of Dermatology · 2015
A randomized, investigator-blinded, parallel-group trial (the ATTRACT study) assigned patients with moderate-to-severe papulopustular rosacea to once-daily ivermectin 1% cream or twice-daily metronidazole 0.75% cream for 16 weeks. At week 16, ivermectin produced a significantly greater reduction in inflammatory lesions from baseline than metronidazole (83.0% versus 73.7%, p<0.001), with the difference already visible at the first assessment at week 3. On the Investigator's Global Assessment, 84.9% of the ivermectin group reached 'clear' or 'almost clear' skin versus 75.4% for metronidazole (p<0.001). Adverse event rates were comparable between arms, with local tolerability rated better for ivermectin, and more patients receiving ivermectin rated their overall improvement as 'excellent' or 'good.'
This is the kind of comparison the azelaic acid data couldn't offer
Strong evidence
Unlike the safety-extension study against azelaic acid, this trial randomized both treatment arms from the same starting point and tracked lesion counts and clinical assessment as primary outcomes — a genuine efficacy showdown, not primarily a safety follow-up. It doesn't make the azelaic acid data irrelevant, but it does give a cleaner answer to 'which works better, faster' when the comparator is metronidazole rather than azelaic acid.
Taken together with the earlier phase III trials against placebo and the longer safety follow-up against azelaic acid, this head-to-head result against metronidazole is a big part of why ivermectin 1% is now considered one of the strongest-performing options among the recognized first-line topical treatments for papulopustular rosacea — though, as with any single trial, it describes an average tendency in a specific population, not a guarantee for every individual patient.
What this means for treatment choice in practice
The trial result — fewer treatment-related adverse events with ivermectin than with azelaic acid under long-term use conditions — is valuable information, but it shouldn't be read as proof that ivermectin is generally "better" than azelaic acid. The two substances have different tolerability profiles: azelaic acid is more often associated with local burning, itching, or skin irritation, especially early in therapy, while ivermectin showed generally good skin tolerability in registration trials. Which option works better for a specific person also depends on the severity of lesions, skin sensitivity, and prior experience with other topical therapies.
Ivermectin 1% is today one of several recognized first-line options for topical treatment of papulopustular rosacea, alongside azelaic acid and metronidazole — the choice between them is a decision for a dermatologist, individually tailored, not a matter of one universally "best" substance confirmed by a single trial.
Check your profile
Not sure which supplements actually make sense for you?
Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.
Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.
The myth that delays proper treatment
Myth
Since it's called "rosacea," the same cosmetics and anti-acne treatments used for ordinary acne should work — you just need to wait longer for results.
Fact
Rosacea and common acne have different underlying disease mechanisms and different first-line treatments. Popular anti-acne products based on strong exfoliating acids or high concentrations of benzoyl peroxide, helpful in common acne, often irritate the already sensitive, reactive skin in rosacea and worsen redness instead of easing it. Correctly distinguishing between these two diseases is a prerequisite for choosing effective treatment.
An added diagnostic difficulty: rosacea is often confused not only with common acne, but also with seborrheic dermatitis, contact dermatitis, lupus erythematosus, or simple sunburn-related redness — some of these conditions require completely different management. Diagnosing it yourself "by eye" and reaching for a random pharmacy cream without consultation carries a real risk of worsening the skin condition or wasting time treating the wrong cause.
Before you reach for any product
Practical steps if you suspect rosacea
Consult a dermatologist to confirm the diagnosis — rosacea is often confused with several other skin conditions requiring different treatment
Don't reach for strong anti-acne products (high-concentration acids, benzoyl peroxide) on your own without consultation — they may worsen redness
Observe and note factors that worsen symptoms (alcohol, spicy foods, hot beverages, stress, UV radiation, high temperature) — this is common and helpful information for your doctor
Use daily sun protection (SPF cream) year-round — UV radiation is one of the more common rosacea-aggravating factors
Choose gentle, hypoallergenic products for daily skincare, avoiding products with alcohol, menthol, or strong fragrances
If your doctor prescribes ivermectin or azelaic acid cream, give the therapy enough time — effects in rosacea usually appear gradually, over several weeks to a few months
Limitations of this data
What this trial doesn't prove
The publication described in this article has several notable limitations worth remembering. First, the available abstract doesn't report the exact number of participants in each group, nor specific percentage values, confidence intervals, or statistical significance levels for the adverse event comparison — the conclusions in the abstract are descriptive, not fully quantitative. Second, as described above, this was not a classic randomized head-to-head comparison of two therapies from the same starting point, which limits the ability to definitively state that ivermectin is "safer" than azelaic acid in a strict, controlled sense. Third, the trial was investigator-blinded (blinding on the evaluating physician's side), not full double-blinding of both parties. Finally, the results apply to a specific form of the disease — papulopustular rosacea — and shouldn't be automatically extended to other forms of rosacea, such as the vascular-erythematous or ocular form.
Question
Short answer
Is rosacea the same as common acne?
No — it's a separate inflammatory disease of the facial blood vessels and skin, requiring different treatment
What did the 2014 trial show?
Ivermectin 1% cream had fewer treatment-related adverse events than azelaic acid 15% over up to 52 weeks of follow-up
Was this a full efficacy showdown between the two substances?
Not exactly — it's mainly long-term safety data from a trial with a non-randomized group setup relative to each other
Is ivermectin generally better than azelaic acid?
There's no clear evidence for that from the safety-extension data — both are recognized first-line options with different tolerability profiles
How does ivermectin compare to metronidazole in a true head-to-head trial?
Better on both lesion reduction (83.0% vs 73.7% at 16 weeks) and clinical assessment (84.9% vs 75.4% rated clear/almost clear), both p<0.001 (Taieb et al. 2015)
Can rosacea be self-diagnosed?
It's not recommended — symptoms are easily confused with other skin conditions, including common acne
Ivermectin vs azelaic acid for rosacea — at a glance
Our editorial recommendation
Ivermectin 1% cream has solid grounds as a treatment option for papulopustular rosacea, confirmed both by phase III trials against placebo and by longer-term safety follow-up against azelaic acid. However, this is not proof of clear superiority over other recognized therapies — it's rather confirmation that ivermectin is a safe, well-tolerated option worth considering alongside azelaic acid and metronidazole, with the final decision belonging to the treating dermatologist.
The most important step in rosacea isn't chemical, it's diagnostic: before anyone chooses between ivermectin and azelaic acid, it's worth being sure this is actually rosacea and not another, similar-looking skin condition.
dr Anna Kowalczyk, VitMode editorial team
Frequently asked questions
Rosacea is a chronic inflammatory disease primarily affecting the blood vessels and innate immunity of the central facial skin, presenting as persistent redness, visible blood vessels, and in some forms, papules and pustules. Common acne, by contrast, results mainly from sebum overproduction, clogged hair follicles, and bacterial proliferation, more often affects younger people, and produces typical comedones. These are two different diseases with different treatments, despite the similar-sounding name.
The trial discussed (Stein Gold et al., 2014) was not a classic, randomized efficacy comparison of both substances from the same starting point — it mainly evaluated long-term safety in a setup where the ivermectin group continued a previously tolerated therapy, while the azelaic acid group was only beginning active treatment after prior placebo. Ivermectin had fewer treatment-related adverse events, but that's not equivalent to proven superior clinical efficacy over azelaic acid.
Some rosacea patients have elevated numbers of Demodex folliculorum mites, which is a studied hypothesis explaining part of the disease mechanism — not a fully confirmed causal fact. Ivermectin acts both as an antiparasitic against Demodex and directly as an anti-inflammatory, so its clinical efficacy doesn't necessarily mean that mite reduction is what's responsible for skin improvement.
In clinical trials, effects were assessed after several weeks to a few months of use, and in the extension trial discussed here, improvement was observed over a total treatment period of up to 40-52 weeks. Rosacea is a chronic disease, so effects appear gradually, and therapy is often continued long-term under a dermatologist's supervision, rather than used briefly like for a single breakout.
Rosacea is a chronic, relapsing disease — available topical therapies, including ivermectin and azelaic acid, control symptoms and reduce inflammatory lesions, but don't constitute a one-time, permanent cure. Many patients require long-term, sometimes seasonally adjusted management, including avoiding known aggravating factors.
Azelaic acid 15% is an established, long-used topical therapy for rosacea with a generally good safety profile. In the trial discussed, the azelaic acid group had more treatment-related adverse events than the group continuing ivermectin, but this difference may partly reflect the trial's setup rather than the substance alone — azelaic acid remains a recognized, safe first-line option.
This isn't recommended without prior dermatological consultation. Facial redness can have many causes besides rosacea, and using the wrong product without a confirmed diagnosis may not only fail to help, but also delay proper treatment or irritate the skin. A dermatologist will confirm the diagnosis and select therapy appropriate to the form and severity of the condition.
Yes — the ATTRACT study (Taieb et al., 2015, British Journal of Dermatology) randomized patients to ivermectin 1% once daily or metronidazole 0.75% twice daily for 16 weeks. Ivermectin showed significantly greater reduction in inflammatory lesions (83.0% vs 73.7%, p<0.001) and a higher proportion of patients rated clear or almost clear (84.9% vs 75.4%, p<0.001), with the advantage already visible at week 3. Unlike the azelaic acid safety-extension data, this trial randomized both arms from the same starting point, making it a cleaner efficacy comparison.
PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging
Anna studied molecular biology at the University of Warsaw, then spent eight years after her PhD in a lab researching the mechanisms of cellular aging and autophagy. She stumbled into science journalism almost by accident — frustrated by how easily her field's findings get oversimplified in the media, she started a blog explaining the biology of aging in plain language. That blog became the seed of VitMode. Today Anna oversees the entire editorial process, holding every piece to the same rigor her old lab demanded: primary sources, methodology checks, and honesty about the limits of the evidence. Outside work, she's a dedicated boulderer.
